ASCO GU Symposium 2022
In-depth coverage of the 2022 ASCO GU Symposium
Study findings associate pre- and posttreatment PSMA expression with prostate-specific antigen response and overall survival.
Trial oncolytic measles virus encoding thyroidal sodium iodide symporter treatment may be effective in patients with UC.
Avelumab plus docetaxel was safe and demonstrated promising efficacy for patients with metastatic urothelial carcinoma.
Study results demonstrate a conclusive pattern of distinct molecular alterations among metastatic sites in patients with RCC.
A study compared genomic profiles of locally advanced or metastatic UCs with squamous differentiation to standard UC.
A follow-up to the VISION trial compared associations of exposure and treatment-emergent adverse events frequency.
Pembrolizumab and lenvatinib didn’t effectively improve clinical outcomes for patients with la/mUC.
Collaborators evaluated trimodality therapy and radical cystectomy and found TMT was effective for select patients with MIBC.
Pembrolizumab plus abiraterone acetate and prednisone may be beneficial for treating chemotherapy-naïve patients with mCRPC.
Researchers quantified the absorbed dose of 177Lu-PSMA-617 in organs at risk for radiotoxicity among patients with mCRPC.
Investigators assessed pembrolizumab, with or without chemotherapy, versus chemotherapy alone in patients with advanced UC.
Researchers assessed 177Lu-PSMA treatment outcomes in patients who would have failed the VISION trial’s inclusion criteria.
Advertisement
Advertisement
